What is MS Phase 3 Study Laquinimod?

Category: Others

false

See also: Clinical Trial

NCT00509145 is a completed randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis. Other study names are MS-LAQ-301, EUDRACT 2007-003226-19.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
0

Commonly reported side effects and conditions associated with MS Phase 3 Study Laquinimod

Side effect Patients
Back pain 1

Duration

Currently using MS Phase 3 Study Laquinimod

Duration Patients
5 - 10 years 1
Last updated:
There are no evaluations for MS Phase 3 Study Laquinimod.